Global high content screening market to reach US$2.19b by 2030

Asia-Pacific is witnessing rapid growth due to the rising prevalence of chronic diseases.

The global high content screening (HCS) market is forecasted to reach US$2.19b by 2030, with a compound annual growth rate of 7.5%, according to MarketsandMarkets research.

The report said that artificial intelligence, expanded applications of HCS in personalised medicine, oncology research, and cell-based assays contribute to market growth.

Amongst applications, drug discovery and development lead the market, with pharmaceutical and biotechnology companies being the largest end users.

The high content imaging platforms segment dominated the market in 2024, owing to their critical role in cellular analysis, drug discovery, and phenotypic screening.

From a regional perspective, Asia-Pacific is witnessing rapid growth due to the rising prevalence of chronic diseases, increasing healthcare investments, and expanding research capabilities.

Countries such as China, India, and Japan are experiencing substantial advancements in biotechnology and drug discovery, contributing to the growing demand for HCS.